HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
Top Cited Papers
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 158 (1), 189-199
- https://doi.org/10.1053/j.gastro.2019.09.041
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Celltrion Healthcare
- AbbVie
- Merck Sharp and Dohme
- Guts UK
This publication has 24 references indexed in Scilit:
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's DiseaseGastroenterology, 2014
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative ColitisGastroenterology, 2014
- Challenges and approaches for the development of safer immunomodulatory biologicsNature Reviews Drug Discovery, 2013
- HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typingJournal of Biomedical Science, 2012
- Pathway-driven gene stability selection of two rheumatoid arthritis GWAS identifies and validates new susceptibility genes in receptor mediated signalling pathwaysHuman Molecular Genetics, 2011
- Association between type 1 diabetes and GWAS SNPs in the southeast US Caucasian populationGenes & Immunity, 2011
- IL10 GGC Haplotype Is Positively and HLA-DQA1*05-DQB1*02 Is Negatively Associated with Radiographic Progression in Undifferentiated ArthritisThe Journal of Rheumatology, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with InfliximabAnnals of Internal Medicine, 2007
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007